65,437 trials
Chronic Hepatitis B
Primary: Percent Probability of Tolerability Failure — 18; 4; 11; 14 percent probability (KM estimate)
Rotavirus Infections
Primary: Number of Participants With Adverse Events. — 14; 12 participants
Spasmodic Torticollis
Primary: Maximum Rates of Extensor Digitorum Brevis (EDB) Muscle M-Wave Amplitude Reduction From Baseline — 9.02; 48.53; 70.95; 81.62 Percentage of Reduction
Cancer
Primary: Toxicity of Celecoxib With Concurrent Weekly Chemotherapy and Radiotherapy in the Treatment of Locally Advanced or Recurrent Squamous Cell Carcinoma of the Head and…
Tooth Erosion
Primary: Adjusted Mean Percent Net Erosion Resistance (NER) of Enamel Specimens Exposed to Test Dentifrice + Test MR Relative to: 1) Test Dentifrice+ Sterile Water Rinse 2)…
Multiple Myeloma
Primary: Phase 1: Participants With Dose-Limiting Toxicities (DLT) in Cycle 1 — 1; 1; 2; 4 participants
Atopic Dermatitis
Primary: Percent Change of Trans Epidermal Water Loss (TEWL) With Use of Eucerin Lotion — 21.4 percent change
Lymphoma, Non-Hodgkin
Primary: Number of Participants (Par.) With Unconfirmed Response (Complete Response, Complete Response/Unconfirmed, or Partial Response), as Assessed by the Investigator — 30…
Carcinoma, Non-Small-Cell Lung
Primary: Maximum Tolerated Dose (MTD)of CP-751,871 in Combination With Paclitaxel and Carboplatin: Phase 1b — NA mg/kg
Glaucoma, Open-Angle
Primary: Percentage of Patients With a Visual Field Improvement in the Study Eye — 12.0; 9.5; 4.2 Percentage of Patients
Autism · Cognition Disorder
Primary: Change in Percentage of Time That Subjects With Autism Spend in REM Sleep. — 9.2 percentage of REM sleep
Upper Respiratory Tract Infection · Lower Respiratory Tract Infection
Primary: Circulating RI-001 Titer — 9.24; 4.85; 1.42 Fold Change
Smoking · Smoking Cessation
Primary: 7-Day Point Prevalence Abstinence From Smoking by Intervention — 43.3; 48.9; 42.3; 49.9 Percentage of participants not smoking — p=.076
Spinal Surgery
Primary: Difference in Plasma Free Hemoglobin (p-Hb) Concentration — 0.1; 0.0 g/l — p=0.6294
Alzheimer Disease · Psychotic Disorders · Agitation
Primary: Relapse by Study Week 32 — 15; 8; 24 participants — p=0.02